Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs.
about
Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and ImagingHDL as a drug and nucleic acid delivery vehicleNano delivers big: designing molecular missiles for cancer therapeutics.Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probeA novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock.Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages.Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.A critical review of lipid-based nanoparticles for taxane delivery.Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles.Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma.Phospholipid nanodisc engineering for drug delivery systems.The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics.Learning from biology: synthetic lipoproteins for drug delivery.Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent.Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier.Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.Development of novel HDL-mimicking α-tocopherol-coated nanoparticles to encapsulate nerve growth factor and evaluation of biodistribution.Nanostructure-Dependent Ratiometric NIR Fluorescence Enabled by Ordered Dye AggregationEfficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticlesSynthesis and Development of Lipoprotein-Based Nanocarriers for Light-Activated Theranostics
P2860
Q28070244-9C84C30A-CE75-4A64-A817-E1B41D6633DDQ28083209-05B8ADBC-57CE-4510-AA38-C0E3F9625D6BQ30470080-9295D573-E63E-4F0E-94F2-C46688B5019FQ33766617-643D61B7-B7EC-469F-9935-9653559968E3Q33868758-D854B7EB-07BF-47D1-B3E3-BE87A9E8881BQ33869944-0B9EE87E-2291-4229-A4B2-FEE17AAF04AEQ34339353-3284F609-656A-4DC8-916D-213E2179A7CFQ34763617-93FC4663-B46D-4454-BD2E-150E6896DE5CQ36360764-9B8BF83C-96D6-45E1-88AA-6E294E9AEB5DQ36997612-F9F2B622-3F92-43CE-826D-EF270FC4F5B4Q37475635-01E92BEE-F019-44B1-B5A2-C8766B28F66AQ38009775-BAB9AD94-3C02-4206-A66A-7EB1766EBD0FQ38149124-818D5CBC-4DEF-4BB7-96ED-ED5BF569B443Q38262882-F710045C-4A64-4D67-81FB-0C9EC3ED5261Q38806244-F142D8E6-DC78-481B-B0FE-37C6C4CF8F6EQ38896948-E6433CC3-7B43-4FA5-BAB2-479661854159Q39007153-FD897FE1-2C58-41D9-AFC4-A5820EA33AD9Q39384668-EEF208BC-2769-4501-8009-69F8153B6D76Q39819856-64F82213-AD66-4648-AC0B-BBA90C07B937Q40175554-3E8F1986-CA1B-4981-A452-F6E850CD7DFAQ42849111-AF5D5BC5-2CF8-4B94-926F-E2E0CA65B696Q59158930-78C5421B-3324-411D-8B4C-FC2C7DA15FFCQ59159078-854D5DD0-731F-4A64-A79F-EB4F08B853C4Q59159093-E87089DB-A953-446D-98F9-D37A4D95E195
P2860
Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prospects and challenges of th ...... lations for anti-cancer drugs.
@en
type
label
Prospects and challenges of th ...... lations for anti-cancer drugs.
@en
prefLabel
Prospects and challenges of th ...... lations for anti-cancer drugs.
@en
P2093
P2860
P356
P1476
Prospects and challenges of th ...... lations for anti-cancer drugs.
@en
P2093
Andras G Lacko
Laszlo Prokai
Walter J McConathy
P2860
P304
P356
10.1517/17425247.4.6.665
P407
P577
2007-11-01T00:00:00Z